IL147641A0 - Beta-carboline pharmaceutical compositions - Google Patents

Beta-carboline pharmaceutical compositions

Info

Publication number
IL147641A0
IL147641A0 IL14764100A IL14764100A IL147641A0 IL 147641 A0 IL147641 A0 IL 147641A0 IL 14764100 A IL14764100 A IL 14764100A IL 14764100 A IL14764100 A IL 14764100A IL 147641 A0 IL147641 A0 IL 147641A0
Authority
IL
Israel
Prior art keywords
beta
pharmaceutical compositions
carboline
carboline pharmaceutical
disintegrant
Prior art date
Application number
IL14764100A
Other languages
English (en)
Original Assignee
Lilly Icos Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22519593&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL147641(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Icos Llc filed Critical Lilly Icos Llc
Publication of IL147641A0 publication Critical patent/IL147641A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL14764100A 1999-08-03 2000-04-26 Beta-carboline pharmaceutical compositions IL147641A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14692499P 1999-08-03 1999-08-03
PCT/US2000/011130 WO2001008686A1 (en) 1999-08-03 2000-04-26 Beta-carboline pharmaceutical compositions

Publications (1)

Publication Number Publication Date
IL147641A0 true IL147641A0 (en) 2002-08-14

Family

ID=22519593

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14764100A IL147641A0 (en) 1999-08-03 2000-04-26 Beta-carboline pharmaceutical compositions
IL147641A IL147641A (en) 1999-08-03 2002-01-15 Pharmaceutical preparations containing (R6, aR12) - 2,3,4,5,6,7,12, a12 - hexahydro - 2 - methyl - 6 - (3, 4 - methylene dioxyphenyl) pyrazino - [2 ', 1': 6, 1] Pyrido [3, 4 –b] Indole - 1, 4– Dion

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL147641A IL147641A (en) 1999-08-03 2002-01-15 Pharmaceutical preparations containing (R6, aR12) - 2,3,4,5,6,7,12, a12 - hexahydro - 2 - methyl - 6 - (3, 4 - methylene dioxyphenyl) pyrazino - [2 ', 1': 6, 1] Pyrido [3, 4 –b] Indole - 1, 4– Dion

Country Status (29)

Country Link
US (2) US7182958B1 (es)
EP (3) EP2338491A3 (es)
JP (2) JP2003505509A (es)
KR (2) KR100738861B1 (es)
CN (1) CN1213754C (es)
AT (1) ATE399554T1 (es)
AU (2) AU776722B2 (es)
BR (1) BR0012863A (es)
CA (1) CA2379948C (es)
CZ (1) CZ304624B6 (es)
DE (1) DE60039357D1 (es)
DK (1) DK1200090T3 (es)
DZ (1) DZ3179A1 (es)
EA (1) EA004872B1 (es)
ES (2) ES2310166T3 (es)
HK (1) HK1044277B (es)
HR (1) HRP20020090B1 (es)
HU (1) HU230660B1 (es)
IL (2) IL147641A0 (es)
MX (1) MXPA02001196A (es)
NO (1) NO321649B1 (es)
NZ (1) NZ516616A (es)
PL (1) PL199137B1 (es)
PT (1) PT1200090E (es)
SI (1) SI1200090T1 (es)
SK (1) SK287869B6 (es)
UA (1) UA72922C2 (es)
WO (2) WO2001008687A1 (es)
ZA (1) ZA200200823B (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6821975B1 (en) 1999-08-03 2004-11-23 Lilly Icos Llc Beta-carboline drug products
ES2310166T3 (es) * 1999-08-03 2009-01-01 Lilly Icos Llc Composicion farmaceutica que contiene tadalafil.
MXPA03009750A (es) 2001-04-25 2004-06-30 Lilly Icos Llc Compuestos quimicos.
EP1321142A1 (en) * 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
DE10207160A1 (de) * 2002-02-20 2003-12-18 Altana Pharma Ag Darreichungsform enthaltend PDE 4-Hemmer als Wirkstoff
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
AU2004220357B2 (en) 2003-03-10 2010-09-30 Astrazeneca Ab Novel process for the preparation of roflumilast
WO2005013964A1 (ja) * 2003-08-08 2005-02-17 Ajinomoto Co., Inc. ナテグリニド含有製剤
ES2421916T3 (es) * 2005-03-16 2013-09-06 Nycomed Gmbh Forma farmacéutica de sabor enmascarado que contiene roflumilast
BRPI0615972A2 (pt) 2005-07-29 2011-05-31 Concert Pharmaceuticals Inc composto isolado, mistura, composição, item de manufatura, uso de um composto, método para determinar a concentração do composto em uma amostra biológica, kit de diagnóstico e método para avaliar a estabilidade metabólica de um composto
FR2898492B1 (fr) * 2006-03-15 2008-06-06 Pierre Fabre Medicament Sa Comprimes orodispersibles de domperidone
KR101140110B1 (ko) * 2006-07-07 2012-06-04 테바 파마슈티컬 인더스트리즈 리미티드 타달라필 및 하나 이상의 담체를 포함하는 고체 조성물
EP1923053A1 (en) 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
WO2008134557A2 (en) * 2007-04-25 2008-11-06 Teva Pharmaceutical Industries Ltd. Solid dosage forms
DE102007028869A1 (de) * 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
EP2042165A1 (de) * 2007-09-28 2009-04-01 Swiss Caps Rechte und Lizenzen AG Hot-Melt-Befüllte Weichkapseln
US20090181975A1 (en) * 2008-01-15 2009-07-16 Forest Laboratories Holdings Limited Nebivolol in the treatment of sexual dysfunction
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
US8586587B2 (en) 2009-02-26 2013-11-19 Thar Pharmaceuticals, Inc. Crystalline molecular complex of tadalafil and methylparaben
DE102009033396A1 (de) 2009-07-16 2011-01-20 Ratiopharm Gmbh Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
DE102009035211A1 (de) 2009-07-29 2011-02-17 Ratiopharm Gmbh Copräzipitate umfassend einen Phosphodiesterase-5-Inhibitor (PDE-5-Inhibitor) und einen pharmazeutisch verträglichen Trägerstoff, ihre Herstellung und Verwendung
WO2011030351A2 (en) 2009-09-03 2011-03-17 Rubicon Research Private Limited Taste - masked pharmaceutical compositions
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
WO2011075801A1 (pt) 2009-12-21 2011-06-30 Acef S.A. Cubebina, lignana dibenzilbutirolactólica, seus derivados semi-sintéticos e sintéticos, bem como outras lignanas e neolignanas como agente vasodilatador na terapia da disfunção erétil
WO2012095151A1 (en) 2010-12-23 2012-07-19 Zaklady Farmaceutyczne Polpharma Sa Solid pharmaceutical dosage forms comprising tadalafil and methods of preparation thereof
WO2012107541A1 (en) 2011-02-10 2012-08-16 Synthon Bv Pharmaceutical composition comprising tadalafil and a cyclodextrin
EP2672959A1 (en) 2011-02-10 2013-12-18 Synthon BV Granulated composition comprising tadalafil and a disintegrant
WO2012107092A1 (en) 2011-02-10 2012-08-16 Synthon Bv Pharmaceutical composition comprising tadalafil and a cyclodextrin
EP2535049A1 (en) 2011-06-17 2012-12-19 Proyecto de Biomedicina Cima, S.L. Tadalafil for the treatment of dementia
US20150320677A1 (en) 2012-08-17 2015-11-12 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Effervescent tablet formulations of dapoxetine and a pde5 inhibitor
US20150231092A1 (en) 2012-08-17 2015-08-20 Sanovell IIac Sanayi Ve Ticaret Anonim Sirketi Novel effervescent sachet formulations of dapoxetine and a pde5 inhibitor
WO2014027979A2 (en) 2012-08-17 2014-02-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Tablet formulations comprising tadalafil and dapoxetine
US20150216798A1 (en) 2012-08-17 2015-08-06 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Novel orally administered pharmaceutical formulations
WO2014125343A1 (en) * 2013-02-12 2014-08-21 Alembic Pharmaceuticals Limited Tadalafil tablet composition with reduced dose strength
WO2014168455A1 (ko) 2013-04-11 2014-10-16 주식회사 씨티씨바이오 분산안정화제로 폴리에틸렌글리콜계 고분자 및/또는 비닐피롤리돈계 고분자를 포함하는 타다라필 유리염기 함유 필름 제형
EP3695841A3 (en) 2013-07-01 2020-11-04 The Research Foundation for the State University of New York Ship inhibition to combat obesity
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
AR099416A1 (es) 2014-02-28 2016-07-20 Lilly Co Eli Terapia combinada para la hipertensión resistente
WO2015200070A1 (en) 2014-06-17 2015-12-30 The Research Foundation For The State University Of New York Ship inhibition to induce expression of granulocyte colony stimulating factor in a subject
WO2016001143A1 (en) 2014-06-30 2016-01-07 Sanovel Ilac Sanayi Ve Ticaret A.S. Orally disintegrating formulations of tadalafil
EP2962684A1 (en) 2014-06-30 2016-01-06 Sanovel Ilac Sanayi ve Ticaret A.S. Orally disintegrating formulations of tadalafil
KR101648051B1 (ko) 2014-09-01 2016-08-12 주식회사 인트로팜텍 타다라필을 포함하는 휴대용 구강붕해정, 및 이의 제조방법
KR101538985B1 (ko) 2014-09-02 2015-07-24 주식회사 서울제약 타다라필 구강붕해필름 및 이의 제조방법
CN104758941A (zh) * 2015-04-27 2015-07-08 浙江永宁药业股份有限公司 一种利用羟丙基纤维素为粘合剂实现快速溶出的口服片剂
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
WO2017104862A1 (ko) * 2015-12-16 2017-06-22 동국제약 주식회사 타달라필 및 두타스테라이드를 포함하는 복합제제 조성물 및 그 제조방법
KR101716878B1 (ko) * 2016-05-12 2017-03-15 주식회사 유유제약 글리세롤 지방산에스테르유도체 또는 프로필렌글리콜 지방산에스테르유도체를 함유한 두타스테리드와 타다라필의 복합 캡슐제제 조성물 및 이의 제조방법
WO2018112258A1 (en) 2016-12-14 2018-06-21 Respira Therapeutics, Inc. Methods and compositions for treatment of pulmonary hypertension and other lung disorders
IT201700015145A1 (it) * 2017-02-10 2018-08-10 Altergon Sa Capsule di gelatina molle ad elevata stabilità
CN106821991A (zh) * 2017-03-21 2017-06-13 南京正科医药股份有限公司 一种微粒径他达拉非的制备方法
KR102646431B1 (ko) 2017-09-29 2024-03-12 한미약품 주식회사 생산성 및 균일성이 개선된 타다라필을 함유하는 고형제제 및 그 제조방법
US11464778B2 (en) 2017-12-26 2022-10-11 Liqmeds Worldwide Limited Liquid oral formulations for sildenafil
PT3510997T (pt) 2018-01-10 2020-10-07 Gap S A Cápsulas de gelatina mole compreendendo uma suspensão de tadalafil
CN112040984A (zh) * 2018-02-07 2020-12-04 斯码瓦有限公司 药物制剂、制备药物制剂的方法和包含其的药物
CN110638770B (zh) * 2019-10-25 2022-04-05 株洲千金药业股份有限公司 他达拉非片剂的制备方法及以该方法制得的片剂
WO2023227185A1 (en) 2022-05-27 2023-11-30 Rontis Hellas S.A. Improved pharmaceutical composition containing tadalafil and nanomilling process for the preparation thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8328929D0 (en) * 1983-10-29 1983-11-30 Sterwin Ag Steroid compounds
US4721709A (en) * 1984-07-26 1988-01-26 Pyare Seth Novel pharmaceutical compositions containing hydrophobic practically water-insoluble drugs adsorbed on pharmaceutical excipients as carrier; process for their preparation and the use of said compositions
JPH0347124A (ja) * 1989-04-20 1991-02-28 Fujisawa Pharmaceut Co Ltd 経口吸収用製剤
JPH0818985B2 (ja) * 1989-05-30 1996-02-28 吉富製薬株式会社 溶出性の改良された製剤組成物
US5294615A (en) * 1993-04-29 1994-03-15 Abbott Laboratories Terazosin polymorph and pharmaceutical composition
FR2710153B1 (fr) * 1993-09-17 1995-12-01 Alpha Mos Sa Procédés et appareils de détection des substances odorantes et applications.
ES2308955T5 (es) * 1993-09-28 2012-04-03 R.P. Scherer Gmbh Fabricación de cápsulas de gelatina blanda
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
GB9514465D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9511220D0 (en) 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
AU5049098A (en) * 1996-11-28 1998-06-22 Novo Nordisk A/S Pharmaceutical formulation
JP4292588B2 (ja) * 1997-01-31 2009-07-08 日産化学工業株式会社 ピリダジノン化合物類の経口製剤
KR100358374B1 (ko) * 1997-07-11 2002-10-25 얀센 파마슈티카 엔.브이. 5-ｈｔ3 및 5-ｈｔ4 매개된 질환에 유용한(+)-노르시사프라이드
NZ504487A (en) * 1997-12-16 2002-11-26 Pfizer Prod Inc Combination of alpha-adrenergic antagonists and cGMP elevators for the treatment of impotence
JP2000178204A (ja) * 1998-10-05 2000-06-27 Eisai Co Ltd ホスフォジエステラ―ゼ阻害剤を含有する口腔内速崩壊性錠剤
JP2000191518A (ja) * 1998-10-19 2000-07-11 Eisai Co Ltd 溶解性の改善された口腔内速崩壊性錠剤
WO2000053148A2 (en) 1999-03-08 2000-09-14 Merck & Co., Inc. Methods and compositions for treating erectile dysfunction
WO2000066114A1 (en) * 1999-04-30 2000-11-09 Lilly Icos Llc Treatment of female arousal disorder
IL135817A0 (en) * 1999-04-30 2001-05-20 Lilly Icos Llc Phosphodiesterase enzyme inhibitors and their use in pharmaceutical articles
US6943166B1 (en) * 1999-04-30 2005-09-13 Lilly Icos Llc. Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
ES2310166T3 (es) * 1999-08-03 2009-01-01 Lilly Icos Llc Composicion farmaceutica que contiene tadalafil.
UA71629C2 (en) * 1999-08-03 2004-12-15 Lilli Icos Llc Composition containing free drug particulate form of ?-carboline (variants), method for its manufacture (variants), and method for treating sexual dysfunction

Also Published As

Publication number Publication date
DK1200090T3 (da) 2013-11-25
AU4491200A (en) 2001-02-19
CA2379948C (en) 2008-03-25
KR100738861B1 (ko) 2007-07-16
EP1200090B1 (en) 2013-09-11
UA72922C2 (uk) 2005-05-16
PL353304A1 (en) 2003-11-03
CA2379948A1 (en) 2001-02-08
EP2338491A3 (en) 2011-11-30
HUP0202513A3 (en) 2004-06-28
PL199137B1 (pl) 2008-08-29
SK287869B6 (sk) 2012-02-03
MXPA02001196A (es) 2003-02-12
JP2003505509A (ja) 2003-02-12
EP2338491A2 (en) 2011-06-29
DZ3179A1 (fr) 2001-02-08
HRP20020090A2 (en) 2003-12-31
WO2001008686A1 (en) 2001-02-08
HK1044277B (zh) 2014-02-28
NZ516616A (en) 2003-07-25
EA004872B1 (ru) 2004-08-26
SI1200090T1 (sl) 2013-12-31
KR20060093355A (ko) 2006-08-24
ZA200200823B (en) 2003-04-30
PT1200090E (pt) 2013-11-25
AU4490900A (en) 2001-02-19
DE60039357D1 (de) 2008-08-14
CN1365282A (zh) 2002-08-21
HUP0202513A2 (en) 2002-10-28
ES2310166T3 (es) 2009-01-01
HRP20020090B1 (hr) 2014-03-28
KR20020014843A (ko) 2002-02-25
CN1213754C (zh) 2005-08-10
US6841167B1 (en) 2005-01-11
EP1200091B1 (en) 2008-07-02
BR0012863A (pt) 2002-04-16
EP1200090A1 (en) 2002-05-02
NO20020532D0 (no) 2002-02-01
WO2001008687A1 (en) 2001-02-08
US7182958B1 (en) 2007-02-27
EP1200091A1 (en) 2002-05-02
NO321649B1 (no) 2006-06-19
HU230660B1 (hu) 2017-06-28
ES2435816T3 (es) 2013-12-23
SK1732002A3 (en) 2002-05-09
CZ2002386A3 (cs) 2002-07-17
CZ304624B6 (cs) 2014-08-13
EA200200118A1 (ru) 2002-06-27
AU776722B2 (en) 2004-09-16
ATE399554T1 (de) 2008-07-15
IL147641A (en) 2007-12-03
NO20020532L (no) 2002-03-26
JP2010163464A (ja) 2010-07-29

Similar Documents

Publication Publication Date Title
HRP20020090A2 (en) Beta-carboline pharmaceutical compositions
HK1069970A1 (en) Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors
CA2363990A1 (en) Use of glycyrrhizin in the treatment of mastitis
HUP0303016A3 (en) Xanthine phosphodiesterase v inhibitors, process for their preparation and pharmaceutical compositions containing them and their use
HUP0304088A3 (en) Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
EP1263468A4 (en) SOLUBILIZING FORMULATION OF INSOLUBLE AGENTS IN WATER, AND PROCESS FOR PREPARING THE SAME
AU7330001A (en) Apparatus and kits for locking and disinfecting implanted catheters
HUP0300602A3 (en) Diazabicyclic central nervous system active agents, pharmaceutical compositions containing them and their use
CA2429020A1 (en) Use of cci-779 as an antineoplastic agent
HUP0204410A3 (en) Pyrimidine-4-one derivatives, process for their preparation, pharmaceutical compositions containing them and their use
AU2001235595A1 (en) 4-heteroaryl-1,4-diazabicyclo(3.2.2)nonane, preparation and therapeutic use thereof
HUP0304085A2 (en) The citrate salt of 5,8,14-triazatetracyclo(10.3.1.02,11.04.9)-hexadeca-2.(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
ITMI20001093A0 (it) Composizioni a rilascio controllato contenenti un principio attivo, preferibilmente melatonina, e processo di preparazione delle stesse.
NO20014050D0 (no) 1-aryl-1,3,5-triazin-4-tion-2,6-dioner, fremstilling derav og anvendelse derav som herbicider
HK1050003A1 (en) Naphthyridine derivatives, processes for their preparation, their use and pharmaceutical compositions comprising them.
GR1003490B (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν αλας παροξετινης
IL153897A0 (en) Pharmaceutical compositions and methods for use
PT1358159E (pt) Tartrato e fosfato de 3,4 diaminopiridina, as suas composições farmacêuticas e as suas utilizações
HUP0301915A2 (hu) Sildenafil és egyéb PDE5 inhibitor hatású vegyületek alkalmazása korai magömlés kezelésére szolgáló gyógyszerkészítmény elżállítására
AU2001292500A1 (en) 1,2,5,10-tetrahydropyridazino(4,5-b)quinoline-1,10-diones and their use for the treatment of pain
HUP0402149A3 (en) Water-soluble phenylpyridazine derivatives, their use and pharmaceutical compositions containing the same
PT1312008E (pt) Aparelhos e estojos para o bloqueio e desinfecção de cateteres implantados
ZA200402401B (en) Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (PDE4) inhibitors.
HK1054873A1 (en) Pharmaceutical composition based on cocaethylene and use thereof for treating psychoactive substancedependence
AU2002214441A1 (en) 1,2,5,10-tetrahydropyridazino(4,5-b)quinoline-1,10-diones and their use for the treatment of pain